CapVest Partners has signed an agreement with Bain Capital and Cinven to acquire a majority stake in STADA Arzneimittel AG.
STADA Arzneimittel manufactures and distributes specialty pharmaceuticals and non-prescription consumer health products. Located in Bad Vilbel, Germany, STADA has evolved from a traditional generics business into a diversified global healthcare platform since its acquisition by Bain Capital and Cinven in 2017.
CapVest Partners is an established European mid-market private equity firm focused on acquiring market leading companies supplying essential products and services. CapVest was formed in 1999 and is based in London.
The lead financial advisors to CapVest were Canson Capital Partners and Centerview Partners.
Bain Capital and Cinven will retain minority stakes in the company after the transaction. The terms of the deal remain undisclosed and are subject to regulatory approvals, with closing anticipated in early 2026.
According to data captured in the LevinPro HC database, this transaction marks the 31st Pharmaceuticals acquisition of 2025. It is also the first Pharmaceuticals deal reported in Germany since the start of the year. There were 66 Pharmaceutical transactions announced throughout all of 2024. Additionally, there have been 109 Pharmaceutical deals announced in Germany since 2000.
